112 related articles for article (PubMed ID: 17586752)
1. Granulocyte colony-stimulating factor-associated complications and increase in leukocyte number.
Ferretti G; Papaldo P
Ann Oncol; 2007 Jun; 18(6):1118-9. PubMed ID: 17586752
[No Abstract] [Full Text] [Related]
2. Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.
Bissett D; Jodrell D; Harnett AN; Habeshaw T; Kaye SB; Evans D; Williams M; Canney PA
Br J Cancer; 1995 Jun; 71(6):1279-82. PubMed ID: 7540038
[TBL] [Abstract][Full Text] [Related]
3. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
[TBL] [Abstract][Full Text] [Related]
4. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
[TBL] [Abstract][Full Text] [Related]
5. The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation.
Peters WP; Kurtzberg J; Atwater S; Borowitz M; Rao M; Currie M; Gilbert C; Shpall EJ; Jones RB; Ross M
Prog Clin Biol Res; 1990; 338():121-8. PubMed ID: 2189135
[No Abstract] [Full Text] [Related]
6. [Use of G-CSF in dose-intensified chemotherapy of breast cancer with FEC (500/75/500 mg/m2 KO) in the adjuvant and metastatic situation].
Konecny G; Nestle-Krämling C; Untch M
Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():301-2. PubMed ID: 7509677
[No Abstract] [Full Text] [Related]
7. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.
Gianni AM; Bregni M; Siena S; Orazi A; Stern AC; Gandola L; Bonadonna G
J Clin Oncol; 1990 May; 8(5):768-78. PubMed ID: 2185337
[TBL] [Abstract][Full Text] [Related]
8. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
Tamura K
Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
[No Abstract] [Full Text] [Related]
9. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.
Taylor KM; Jagannath S; Spitzer G; Spinolo JA; Tucker SL; Fogel B; Cabanillas FF; Hagemeister FB; Souza LM
J Clin Oncol; 1989 Dec; 7(12):1791-9. PubMed ID: 2479719
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
ten Bokkel Huinink WW; Lustig V; Dubbelman R; Hiemstra A; Rodenhuis S
Eur J Cancer; 1997 Aug; 33 Suppl 7():S23-5. PubMed ID: 9486100
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
Mamounas EP; Anderson S; Wickerham DL; Clark R; Stoller R; Hamm JT; Stewart JA; Bear HD; Glass AG; Bornstein R
Am J Clin Oncol; 1994 Oct; 17(5):374-81; discussion 382. PubMed ID: 7522393
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor and marrow transplantation.
Sauter C
N Engl J Med; 1988 Sep; 319(13):870-1. PubMed ID: 3045556
[No Abstract] [Full Text] [Related]
14. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
15. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy.
Venturini M; Del Mastro L; Melioli G; Balleari E; Garrone O; Pasquetti W; Bason C; Ghio R; Bruzzi P; Rosso R
Cancer; 1994 Oct; 74(8):2300-6. PubMed ID: 7522948
[TBL] [Abstract][Full Text] [Related]
16. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
17. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.
Brandt SJ; Peters WP; Atwater SK; Kurtzberg J; Borowitz MJ; Jones RB; Shpall EJ; Bast RC; Gilbert CJ; Oette DH
N Engl J Med; 1988 Apr; 318(14):869-76. PubMed ID: 3281007
[TBL] [Abstract][Full Text] [Related]
18. [Phase I, II studies of recombinant granulocyte colony stimulating factor (gamma hG-CSF)].
Ogawa M
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3537-42. PubMed ID: 2479337
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
Kwasny W; Kornek G; Haider K; Valencak J; Ulrich-Pur H; Penz M; Lang F; Depisch D; Scheithauer W
Breast Cancer Res Treat; 2000 Oct; 63(3):235-41. PubMed ID: 11110057
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
